Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 2, 2014, Pages 253-258

  Meletis, G ^a   Vavatsi, N ^b   Exindari, M ^b   Protonotariou, E ^b   Sianou, E ^a   Haitoglou, C ^b   Sofianou, D ^a   Pournaras, S ^c   Diza, E ^b  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; HUMANS; IMIPENEM; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SELECTION, GENETIC; THIENAMYCINS;

EID: 84893954425     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-1952-3     Document Type: Article

References (26)

1. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E (2012) Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia 16:303-307
2. Poole K (2011) Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2:65
3. Quale J, Bratu S, Gupta J, Landman D (2006) Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50:1633-1641
4. Clinical and Laboratory Standards Institute (2007) Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement M100-S17. CLSI, Wayne
5. European Committee on Antimicrobial Susceptibility Testing (2013) Breakpoint tables for interpretation of MICs and zone diameters, version 3.0 January 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk- test-documents/EUCAST-Breakpoint-table-v-3.0.pdf
6. Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, Themeli-Digalaki K, Tsakris A (2012) Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. J Clin Microbiol 50:3747-3750
7. Lee K, Lim YS, Yong D, Yum JH, Chong Y (2003) Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 41:4623-4629
8. Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y (2006) Detection of extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:2990-2995
9. Maniati M, Ikonomidis A, Mantzana P, Daponte A, Maniatis AN, Pournaras S (2007) A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD. J Antimicrob Chemother 60:132-135
10. Pournaras S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, Legakis NJ, Maniatis AN (2005) Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity. J Antimicrob Chemother 56:761-764
11. Dunne WM Jr, Hardin DJ (2005) Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 43:5945-5949
12. Wolska K, Szweda P (2008) A comparative evaluation of PCR ribotyping and ERIC PCR for determining the diversity of clinical Pseudomonas aeruginosa strains. Pol J Microbiol 57:157-163
13. Miyakis S, Pefanis A, Tsakris A (2011) The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis 53:177-184
14. Souli M, Galani I, Giamarellou H (2008) Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13.pii:19045
15. Mavroidi A, Tsakris A, Tzelepi E, Pournaras S, Loukova V, Tzouvelekis LS (2000) Carbapenem-hydrolysing VIM-2 metallo-beta-lactamase in Pseudomonas aeruginosa from Greece. J Antimicrob Chemother 46:1041-1042
16. Giakkoupi P, Petrikkos G, Tzouvelekis LS, Tsonas S, Legakis NJ, Vatopoulos AC, WHONET Greece Study Group (2003) Spread of integron-associated VIM-type metallo-beta-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol 41:822-825
17. Meletis G, Tzampaz E, Protonotariou E, Sofianou D (2010) Emergence of Klebsiella pneumoniae carrying blaVIM and blaKPC genes. Hippokratia 14:139-140
18. Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouvelekis LS (2009) Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. Antimicrob Agents Chemother 53:4048-4050
19. Martínez T, Vázquez GJ, Aquino EE, Ramírez-Ronda R, Robledo IE (2012) First report of a Pseudomonas aeruginosa clinical isolate co-harbouring KPC-2 and IMP-18 carbapenemases. Int J Antimicrob Agents 39:542-543
20. Correa A, Montealegre MC, Mojica MF, Maya JJ, Rojas LJ, De La Cadena EP (2012) First report of a Pseudomonas aeruginosa isolate coharboring KPC and VIM carbapenemases. Antimicrob Agents Chemother 56:5422-5423
21. Woodford N, Turton JF, Livermore DM (2011) Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736-755
22. Rodríguez-Martínez JM, Poirel L, Nordmann P (2009) Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:4783-4788
23. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B (2005) Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113:187-196
24. Farra A, Islam S, Strålfors A, Sörberg M, Wretlind B (2008) Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents 31:427-433
25. Moya B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A (2012) Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 56:4771-4778
26. Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, Marty N, Grattard F, Mariani-Kurkdjian P, Bingen E, Husson MO, Couetdic G, Plésiat P (2007) Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 51:3531-3536